Semi-Annual Consolidated Statement Of Income

K Pharma,Inc. - Filing #7344418

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Semi-annual consolidated statement of income
Statement of income
Net sales	—	1,000,000,000 JPY	—	—	—	—	JPY	—
Cost of sales	—	90,000,000 JPY	—	—	—	—	JPY	—
Ordinary profit (loss)	—	344,184,000 JPY	—	—	—	—	-359,233,000 JPY	—
Gross profit (loss)	—	910,000,000 JPY	—	—	—	—	JPY	—
Selling, general and administrative expenses
Remuneration for directors (and other officers)	—	69,200,000 JPY	—	—	—	—	50,386,000 JPY	—
Taxes and dues	—	29,071,000 JPY	—	—	—	—	20,419,000 JPY	—
Selling, general and administrative expenses	—	543,942,000 JPY	—	—	—	—	353,772,000 JPY	—
Extraordinary losses	—	43,107,000 JPY	—	—	—	—	31,293,000 JPY	—
Profit (loss) before income taxes	—	301,076,000 JPY	—	—	—	—	-390,526,000 JPY	—
Operating profit (loss)	—	366,057,000 JPY	—	—	—	—	-353,772,000 JPY	—
Income taxes - current	—	40,746,000 JPY	—	—	—	—	1,900,000 JPY	—
Non-operating income
Interest income	—	16,000 JPY	—	—	—	—	7,000 JPY	—
Non-operating income	—	66,000 JPY	—	—	—	—	52,000 JPY	—
Non-operating expenses
Non-operating expenses	—	21,939,000 JPY	—	—	—	—	5,514,000 JPY	—
Income taxes	—	40,746,000 JPY	—	—	—	—	1,900,000 JPY	—
Profit (loss)	260,330,000 JPY	260,330,000 JPY	260,330,000 JPY	260,330,000 JPY	-392,427,000 JPY	-392,427,000 JPY	-392,427,000 JPY	-392,427,000 JPY
Extraordinary losses
Impairment losses	—	43,107,000 JPY	—	—	—	—	31,293,000 JPY	—